T
Tobie J. de Villiers
Researcher at University of Cape Town
Publications - 6
Citations - 2212
Tobie J. de Villiers is an academic researcher from University of Cape Town. The author has contributed to research in topics: Randomized controlled trial & Placebo-controlled study. The author has an hindex of 5, co-authored 6 publications receiving 1729 citations.
Papers
More filters
Journal ArticleDOI
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.
Siobán D. Harlow,Margery Gass,Janet E. Hall,Roger A. Lobo,Pauline M. Maki,Robert W. Rebar,Sherry Sherman,Patrick M. Sluss,Tobie J. de Villiers +8 more
TL;DR: Application of the STRAW + 10 staging system should improve comparability of studies of midlife women and facilitate clinical decision making and provide a more comprehensive basis for assessing reproductive aging in research and clinical contexts.
Journal ArticleDOI
Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging.
Siobán D. Harlow,Margery Gass,Janet E. Hall,Roger A. Lobo,Pauline M. Maki,Robert W. Rebar,Sherry Sherman,Patrick M. Sluss,Tobie J. de Villiers +8 more
TL;DR: STRAW +10 provides a more comprehensive basis for assessing reproductive aging in research and clinical contexts and should improve comparability of studies of midlife women and facilitate clinical decision making.
Journal ArticleDOI
Executive summary of the Stages of Reproductive Aging Workshop + 10
Siobán D. Harlow,Margery Gass,Janet E. Hall,Roger A. Lobo,Pauline M. Maki,Robert W. Rebar,Sherry Sherman,Patrick M. Sluss,Tobie J. de Villiers +8 more
TL;DR: STRAW + 10 provides a more comprehensive basis for assessing reproductive aging in research and clinical contexts and should improve comparability of studies of midlife women and facilitate clinical decision making.
Journal ArticleDOI
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
Santiago Palacios,Stuart L. Silverman,Tobie J. de Villiers,Amy B. Levine,Stefan Goemaere,Jacques P. Brown,Fiorenzo De Cicco Nardone,Robert D. Williams,Teresa Hines,Sebastian Mirkin,Arkadi Chines +10 more
TL;DR: Efficacy and safety of bazedoxifene are sustained across 7 years in postmenopausal women with osteoporosis, with similar adverse Events, serious adverse events, and study discontinuations in all groups.